InflamaX Pharmaceuticals Completes Angel Financing to Advance Innovative Immuno-Inflammatory Therapeutics

VCBeat has learned exclusively that Anyanda Pharmaceutical Technology (Guangzhou) Co., Ltd. (“Anyanda Pharma”), a clinical-stage innovative drug R&D company specializing in the field of immune inflammation, officially announced today the completion of its tens-of-millions-of-yuan angel financing round, exclusively led by Redhill Capital. This fully demonstrates the recognition, support, and confidence of the pharmaceutical investment community in Anyanda Pharma’s new drug pipeline layout, talent team building, and future development plans. The funds from this round will be primarily used to initiate Anyanda Pharma’s core pipeline, namelyMAX-001Conduct Phase I clinical trials both domestically and internationally, and further build a team with international and pharmaceutical industry experience to accelerate the R&D and industrialization of innovative drugs in the field of immune-inflammatory diseases.

Regarding the successful completion of this angel financing round,Micky D. Tortorella, Founder and CEO of Anyanda PharmaceuticalsHe stated, “We sincerely appreciate Redhill Capital’s recognition and strong support for Anyanda Pharmaceuticals, which is particularly crucial for a startup biopharmaceutical company. Since its inception, Anyanda Pharmaceuticals has clearly defined its strategic direction, focusing on the research and development of innovative drugs in the field of immune-inflammatory diseases. Through approximately one year of strategic development and layout, the company has established a highly competitive and differentiated drug R&D pipeline and has initially completed the formation of its R&D and management teams. I believe this financing will significantly accelerate the development progress of our R&D pipeline, particularly by facilitating the early entry of our lead candidate, MAX-001, into clinical trials. We also warmly welcome more investors to collaborate with Anyanda Pharmaceuticals to accelerate the translation and commercialization of related innovative drugs, thereby contributing to addressing significant unmet clinical needs in the field of immune-inflammatory diseases both regionally and globally.”

Dr. Li Jie, Partner at Redhill Capital“It has become evident that PD-1/L1 antibody drugs have emerged as first-line therapies for various advanced solid tumors; however, approximately 75% of patients develop drug resistance. Therefore, overcoming this resistance represents immense therapeutic potential. Anyanda Pharma’s inaugural pipeline targets the mechanisms of PD-1/L1 antibody resistance in advanced solid tumors, successfully attracting strong interest from the Redhill Capital team. The founder, Micky, has dedicated over 25 years to basic research on immune-inflammatory diseases and new drug development, boasting extensive R&D experience at international pharmaceutical companies such as DuPont, Pharmacia, and Pfizer. He also served for many years as Chief Technology Officer at the Drug R&D Center of the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, where he led the establishment of a highly productive small-molecule drug discovery platform. Within just about one year, the company has strategically laid out four first-in-class (FIC) or best-in-class (BIC) flagship pipelines in the field of immune-inflammatory diseases, demonstrating the Anyanda Pharma team’s efficient execution capabilities. Redhill Capital will join hands with the Anyanda Pharma team to continue supporting its growth and expansion.”

Anyanda Pharma, established in 2022, is a clinical-stage biopharmaceutical technology company headquartered in Guangzhou. The company focuses on developing innovative drugs targeting immuno-inflammatory pathways to treat various conditions, including cancer, pain, neurological disorders, and osteoarthritis. Anyanda Pharma boasts a top-tier medicinal chemistry team and maintains a robust global network and partnerships. The company’s scientific team operates on the premise that the tissue microenvironment dictates how the body’s immune system responds to its surroundings; even minor alterations in the extracellular matrix can lead to excessive or insufficient immune/inflammatory responses, thereby driving disease onset and progression. Its drug candidates are specifically designed to target key mechanisms and pathways within the tissue microenvironment, aiming to correct pathological immuno-inflammatory responses. Currently, Anyanda Pharma has four clinical candidate drugs in development, while its preclinical drug discovery division is actively synthesizing and identifying new compounds targeting various key immuno-inflammatory targets.

Redhill Capital is a venture capital firm dedicated to the healthcare and medical industry. It has systematically invested across multiple sectors, including innovative medical technologies such as high-value consumables, in vitro diagnostic reagents, consumer healthcare, and digital health, as well as innovative drugs, biotechnology companies, and novel medical services. Committed to delivering strong returns to its investors, Redhill Capital leverages capital to accelerate the research, development, and commercialization of modern medical and pharmaceutical technologies. Its mission is to enhance the overall health and well-being of the population and to become a trusted, enduring, and premier medical fund management company.

Guangzhou, Guangdong, China – October 20th 2023

InflamaX Pharmaceuticals Ltd, a clinical stage drug discovery company that specializes in making new medicines that target immuno-inflammation is announcing that it has completed an angel-round financing of several tens of millions of RMB, exclusively led by Redhill Capital. This fully demonstrates the recognition and support of the pharmaceutical investment community in the company’s new drug pipeline layout, team construction and future development plans. This round of financing will be used to launch Phase I clinical trials of the pioneering pipeline, MAX-001, at home and abroad, and to further recruit talents with both international and pharmaceutical industry experience to accelerate the development and industrialization of innovative drugs in the field of immuno-inflammation.

Regarding the successful completion of angel-round financing, Micky D. Tortorella, founder and CEO of InflamaX Pharmaceuticals, commented: “We sincerely thank Redhill Capital for its recognition and strong support of our company. I consider it particularly critical for a start-up biotech company. Our company has clearly defined its strategic development direction at the beginning of its establishment, which is to focus on the R&D of innovative drugs in the field of immuno-inflammation. After just one year of development, InflamaX has established a highly competitive and differentiated pipeline. And the R&D and management team have been initially formed. I strongly believe this financing will significantly accelerate the development progress of the company’s pipeline, especially to help our pioneering pipeline, MAX-001, enter into clinical stage. We also sincerely welcome more investors to cooperate with our team to accelerate the implementation and transformation of relevant innovative drugs, which would definitely contribute to address the unmet medical needs in the field of immuno-inflammation in the region and even throughout the world.”

Dr. Jie Li, partner of Redhill Capital, commented: “PD-1/L1 antibody drugs have become first-line treatment for many advanced solid tumors, however, 75% of the patients endure drug resistance. Therefore, any drug that can overcome this kind of resistance represents an extremely promising therapy. InflamaX’s pioneering pipeline MAX-001, which is exactly designed to overcome this type of resistance, has caught the eye of Redhill team. Besides, we’re well noticed that the founder and CEO, Micky, has been in the basic research field and drug development community of immune-inflammatory diseases for more than 25 years. Moreover, Micky has served as the CTO of Drug Discovery Pipeline at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences for many years, leading the establishment of the small molecule drug discovery platform with fruitful results.. In just about a year of development, InflamaX’s laid out four FIC/BIC pipelines in the field of immuno-inflammation, reflecting an efficient execution capability of the team. Redhill Capital will join hands with the team and provide continuous supports.”

About InflamaX:

Founded in 2022, InflamaX is a clinical-stage biotechnology company located in Guangzhou that specializes in making new medicines that target immuno-inflammation as a means for treating various diseases including cancers, pain, neurological diseases and osteoarthritis. InflamaX boasts a first rate medicinal chemistry team and a strong network and collaborations throughout the world. It is our belief that the tissue microenvironment determines how the immune system responds to its surrounding environment. Small changes in the extracellular matrix can cause an over-reaction or under-reaction in the immune/inflammatory response resulting in disease. Our drugs target key mechanisms and pathways in the tissue microenvironment that correct this incorrect immune/inflammatory response.  We currently have 4 clinical candidate drugs in our portfolio and also have a preclinical drug discovery arm that is making new compounds against various immuno-inflammation based targets.

About Redhill:

Redhill Capital is a venture capital focusing on the medical and health industry. The layout includes high-value consumables, in vitro diagnostic reagents, consumer medicine, digital medicine and other innovative medical technologies, as well as innovative drugs, bio-tech companies, new medical services and other fields. Redhill Capital is committed to rewarding its investors with excellent performance, and hopes to use the power of capital to accelerate the research and development and marketization of modern medicines and medical technology, so as to improve the level of medical care and health for the whole world, and become a trustworthy and everlasting excellent medical fund management company.